Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 316 participants.

Also called NCT07028749

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 316 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07028749
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Canada, New Zealand (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07028749. Randomized; quadruple masking; primary purpose treatment. Start 2025-06-30 (actual); primary completion 2027-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
Acronym
TYDAL-TIMI 78
Condition
Hypertriglyceridemia
Intervention (Drug)
MAR001
Intervention (Drug)
Placebo
Lead sponsor
Marea Therapeutics (class: industry)
Collaborator
The TIMI Study Group (class: other)

Record details

Record id
cardio:ct-nct07028749
Content hash
55f9ca6f3baf63187c50e9c3199a16323d6b9bbf737f9414eae3239ec66b5974